CoAlign Innovations, Inc. Announces FDA Clearance of AccuLIF® Expandable Interbody Device Product Line for Lateral Surgical ApproachesAugust 19, 2013 8:30 am | by Business Wire | News | Comments
CoAlign Innovations, Inc. announced today that its AccuLIF® XL lateral expandable interbody fusion devices have received marketing clearance from the United States Food and Drug Administration. This new product line addresses fusion procedures employing the lateral approach.
Journal of the American College of Surgeons study reports that new web-based tool effectively aids the informed decision-making process by educating patients about their operations; its use may become a quality reporting requirement for surgeons
University of Washington engineers have created a new wireless communication system that allows devices to interact with each other without relying on batteries or wires for power. The new communication technique, which the researchers call “ambient backscatter,” takes advantage of the TV and cellular transmissions that already surround us around the clock.
Cardica and its distribution partner Century Medical are shooting for Japanese regulatory approval for the stapling cartridge components of Cardica's MicroCutter Xchange surgical device. Redwood City, Calif.-based Cardica sent in the cartridge design validation application to Japan's Pharmaceuticals & Medical Devices Agency today.
A plastic material already used in absorbable surgical sutures and other medical devices shows promise for continuous administration of antibiotics to patients with brain infections, scientists are reporting in a new study. Use of the material, placed directly on the brain’s surface, could reduce the need for weeks of costly hospital stays now required for such treatment.
The demand for less invasive devices is persistently growing, putting the pressure on engineers to put forth quality, innovative products, all while staying ahead of the competition. ER and surgical robotics and minimally invasive devices are currently holding the spotlight, seeing some of the most promising growth and innovation.
A new analysis has found that a type of radiation therapy called carbon ion radiotherapy can control cancer growth and prolong survival in patients with spinal tumors. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the treatment is a promising alternative for patients whose spinal tumors cannot be surgically removed.
Cardica, Inc. and Century Medical, Inc. today announced that Century Medical filed for regulatory approval of Cardica's MicroCutter XCHANGE™ 30 cutting and stapling cartridge in Japan. The submission to the Pharmaceuticals and Medical Devices Agency (PMDA) includes design, validation and verification data for the MicroCutter XCHANGE 30 cartridges.
Former President George W. Bush’s recent heart stent operation will further increase the popularity of what is often an unnecessary and wasteful procedure, says an analyst with research and consulting firm GlobalData. The ex-US President received a stent to prop open a clogged coronary artery on Tuesday morning, following a regularly scheduled visit to his doctor.
Surgery to relieve the damaging pressure caused by hemorrhaging in the brain is a perfect job for a robot. That is the basic premise of a new image-guided surgical system under development at Vanderbilt University. It employs steerable needles about the size of those used for biopsies to penetrate the brain with minimal damage and suction away the blood clot that has formed.
RTI Surgical Inc. has announced today the full market launch of the Tritium Sternal Cable Plating System for closing median sternotomies following open heart procedures. The Tritium SCP System enhances the stability and strength of traditional sternal closure techniques by using a unique load-sharing concept.
Welcome to the Pulse, brought to you by MDT TV. Today, we're implanting an MRI-safe spinal cord stimulator, sorting blood with a microchip, building robots out of biocompatible hydrogel, and making hydrogel move with light.
Over 50% of U.S. News & World Report's "Best Heart Hospitals" Are Certified to Implant the SynCardia Total Artificial HeartAugust 8, 2013 8:45 am | by PR Newswire | News | Comments
SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that over half of the top 50 centers honored in U.S. News & World Report's "Best Hospitals" list for cardiology and heart surgery for 2013-2014, offer the SynCardia temporary Total Artificial Heart.
The Optease Retrievable Vena Cava Filter is used for the prevention of recurrent pulmonary embolism in patients under specific situations. The device is implanted into the inferior vena cava and is designed to be retrieved when the patient no longer requires a filter.
Stryker Interventional Spine announced the clearance of 510(k)s for two additional products to its portfolio. Venom RF Cannula and Venom Electrode are designed to provide an effective and minimally invasive treatment for facet joint pain. The launch of the 11g iVAS Balloon System addresses the surgical trend of shifting toward less invasive treatment options.
Ground-breaking research is harnessing the unique properties of diamonds to develop a new generation of lasers that could lead to many benefits, from better treatment of skin complaints and diabetes-related eye conditions to improved pollution monitoring and aeronautical engineering.
A new study reports that peripherally inserted central catheters (PICCs) do not reduce the risk of central line associated bloodstream infections (CLABSIs) in hospitalized patients. PICCs have become one of the most commonly used central venous catheters (CVCs) in healthcare settings since they are considered easier and safer to use, with less risk of CLABSIs.
Neurosurgeons at The Ohio State University Wexner Medical Center are among the first in the United States to successfully implant an MRI-safe spinal cord stimulator to help patients suffering from chronic back or limb pain. Neurosurgeons Dr. Ali Rezai and Dr. Milind Deogaonkar performed the surgery Aug. 5...
Ocular Therapeutix, Inc. announced today that the U.S. Food and Drug Administration (FDA) has scheduled an Ophthalmic Devices Panel meeting on September 19, 2013 to discuss, make recommendations, and vote on the company’s Premarket Approval (PMA) Application for the ReSure Sealant.
Healthcare giant Johnson and Johnson says it is pleased to put a legal dispute behind it after a Chinese court ordered it to pay compensation to a former distributor under an anti-monopoly law. Thursday's ruling said Johnson & Johnson was guilty of "vertical monopoly" for setting minimum prices its distributors charged for surgical sutures.
A novel interactive 3Dimensional (3D) simulation platform offers surgical residents a unique opportunity to hone their diagnostic and patient management skills, and then have those skills accurately evaluated according to a new study appearing in the August issue of the Journal of the American College of Surgeons.
Researchers from North Carolina State University have developed a new technique for creating devices out of a water-based hydrogel material that can be patterned, folded and used to manipulate objects. The technique holds promise for use in "soft robotics" and biomedical applications.
An FDA advisory panel is slated to convene Sept. 19 to review the pre-market approval application for Ocular Therapeutix Inc.'s ReSure sealant. The FDA's Ophthalmic Devices Panel will review the PMA for the ReSure product, a hydrogel designed to seal incisions to the cornea made during cataract or intraocular lens placement surgery.
Despite being a rare event, wrong site surgery is the number-one operating room safety concern for 65 percent of OR nurses in the United States, according to a new national survey conducted by Medline Industries, Inc. According to the Joint Commission Center for Transforming Healthcare, wrong site surgery occurs as often as 40 times per week in the U.S
Digirad Corporation announced today that it has signed an agreement to sell its "Trapper" Surgical Imaging Technology previously under development, as well as license "Trapper" related technology to Novadaq Technologies, a publicly-traded developer of clinically-relevant imaging solutions for use in surgical and outpatient wound care procedures.